Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from EBOS Group Limited ( (AU:EBO) ).
EBOS Group Limited has reported that 29,742 performance rights have lapsed under its equity arrangements, leaving a total of 1,451,060 performance rights on issue. The change is relatively small in scale but provides updated transparency on the company’s outstanding performance-based equity instruments, information that may be relevant for investors tracking potential share dilution and executive or employee incentive structures.
The most recent analyst rating on (AU:EBO) stock is a Hold with a A$26.00 price target. To see the full list of analyst forecasts on EBOS Group Limited stock, see the AU:EBO Stock Forecast page.
More about EBOS Group Limited
EBOS Group Limited is a New Zealand- and Australia-based healthcare and pharmaceutical products company, operating across distribution and related services to the medical and pharmacy sectors in both markets.
Average Trading Volume: 120,357
Technical Sentiment Signal: Sell
Current Market Cap: A$4.88B
Learn more about EBO stock on TipRanks’ Stock Analysis page.